111 assets in Rectal Carcinoma

Therapeutic assets addressing Rectal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Capecitabine Rectal Carcinoma	Gustave Roussy, Cancer Campus, Grand Paris	P4	BBB (73)
Fluorouracilum Rectal Carcinoma	Gustave Roussy, Cancer Campus, Grand Paris	P3	BBB (72)
Oxaliplatin Rectal Carcinoma	Gustave Roussy, Cancer Campus, Grand Paris	P3	BBB (72)
Irinotecan Rectal Carcinoma	SCRI Development Innovations, LLC	P3	BB (71)
Cetuximab Rectal Carcinoma	Tang-Du Hospital	P2	BB (69)
Pertuzumab Rectal Carcinoma	SWOG Cancer Research Network	P2	BB (66)
Tislelizumab Rectal Carcinoma	Fudan University	P3	BB (64)
Dasatinib Rectal Carcinoma	Anne Noonan	P2	B (63)
Neomycin Rectal Carcinoma	Helsinki University Central Hospital	P4	B (63)
Serplulimab Rectal Carcinoma	Fudan University	P3	B (63)
Vandazole Rectal Carcinoma	Helsinki University Central Hospital	P4	B (63)
Fruquintinib Rectal Carcinoma	SCRI Development Innovations, LLC	P2/3	B (61)
Marcaine Rectal Carcinoma	University Hospital of North Norway	P4	B (61)
Cyclophosphamide Rectal Carcinoma	University Hospital, Geneva	P2	B (60)
Tipiracil Rectal Carcinoma	Sun Yat-sen University	P2	B (60)
Trastuzumab Rectal Carcinoma	Peking Union Medical College Hospital	P2	B (60)
Trifluridine Rectal Carcinoma	Sun Yat-sen University	P2	B (60)
Envafolimab Rectal Carcinoma	池畔	P3	B (59)
Macrogols Rectal Carcinoma	Helsinki University Central Hospital	P4	B (59)
Nivolumab Rectal Carcinoma	University of Colorado, Denver	P2	B (59)
Pucotenlimab Rectal Carcinoma	Sun Yat-sen University	P3	B (59)
Tas-102 Rectal Carcinoma	Shandong Cancer Hospital and Institute	P3	B (59)
Binimetinib Rectal Carcinoma	University of California, San Francisco	P2	B (58)
Celecoxib Rectal Carcinoma	Zhejiang University	P3	B (58)
Disitamab Vedotin Rectal Carcinoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P2	B (58)
Trametinib Rectal Carcinoma	City of Hope Medical Center	P2	B (58)
Palbociclib Rectal Carcinoma	National Cancer Institute (NCI)	P2	B (57)
Atezolizumab Rectal Carcinoma	Hoffmann-La Roche	P2	CCC (55)
Pembrolizumab Rectal Carcinoma	University Hospital, Geneva	P2	CCC (55)
Regorafenib Rectal Carcinoma	M.D. Anderson Cancer Center	P2	CCC (55)
Xintilimab Rectal Carcinoma	Changhai Hospital	P2/3	CCC (55)
Ctx-009 Rectal Carcinoma	Compass Therapeutics	P2	CCC (54)
Glycerin,Anhydrous Rectal Carcinoma	University of Aarhus	P3	CCC (54)
Loperamide Rectal Carcinoma	Ohio State University Comprehensive Cancer Center	P3	CCC (54)
Raltitrexed Rectal Carcinoma	Fudan University	P2	CCC (54)
Terelizumab Rectal Carcinoma	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	P2	CCC (54)
Capivasertib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Citrus Flavonoid Tablets (Alvenor) Rectal Carcinoma	Sixth Affiliated Hospital, Sun Yat-sen University	P2	CCC (53)
Crizotinib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Dabrafenib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Defactinib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Fexagratinib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Gsk-2636771 Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Mesalamine Rectal Carcinoma	AHS Cancer Control Alberta	P2	CCC (53)
Osimertinib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Relatlimab Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Sapanisertib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)

Showing 1 to 50 of 111 assets

PreviousPage 1 of 3Next